Prostate Cancer - Results from #20

AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer. October 30, 2024

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer. October 30, 2024

Identifying the best candidate for focal therapy: a comprehensive review. October 30, 2024

Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer. October 30, 2024

Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. October 30, 2024

Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study. October 30, 2024

What's in a Name? Why Words Matter in Advanced Prostate Cancer. October 30, 2024

Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? October 29, 2024

Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. October 29, 2024

The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). October 29, 2024

Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer. October 29, 2024

Trends in Age and Prostate-Specific Antigen at Prostate Cancer Diagnosis between 2010 and 2019. October 29, 2024

Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. October 28, 2024

The hidden costs: a qualitative analysis exploring the experience of prostate cancer treatment-related side effects on sexual function and urinary incontinence among Black survivors and their caregivers. October 28, 2024

Profiling of urinary extracellular vesicle protein signatures from patients with cribriform and intraductal prostate carcinoma in a cross-sectional study. October 28, 2024

Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. October 28, 2024

Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer. October 28, 2024

N-linked fucosylated glycans are biomarkers for prostate cancer with a neuroendocrine and metastatic phenotype. October 25, 2024

The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE). October 25, 2024

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. October 25, 2024

Page 2 of 1435